Outset Medical (OM) to Release Earnings on Thursday

Outset Medical (NASDAQ:OM) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.7167) per share and revenue of $28.9670 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Outset Medical (NASDAQ:OM) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The company had revenue of $27.86 million for the quarter, compared to analysts’ expectations of $28.90 million. Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. On average, analysts expect Outset Medical to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Outset Medical Stock Performance

Shares of NASDAQ OM opened at $5.22 on Wednesday. The company has a market cap of $96.78 million, a P/E ratio of -1.25 and a beta of 1.96. Outset Medical has a 52-week low of $3.00 and a 52-week high of $17.20. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.97 and a current ratio of 6.29. The firm’s fifty day moving average is $4.58 and its two-hundred day moving average is $4.27.

Analyst Ratings Changes

A number of brokerages have recently weighed in on OM. TD Cowen restated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Wednesday, June 24th. Finally, Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Outset Medical currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Insider Buying and Selling

In other Outset Medical news, CFO Renee Gaeta sold 17,672 shares of Outset Medical stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total value of $87,299.68. Following the completion of the transaction, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at $561,939.82. This trade represents a 13.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 25,337 shares of company stock worth $115,660 in the last three months. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in Outset Medical during the second quarter worth approximately $34,000. BNP Paribas Financial Markets lifted its stake in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Outset Medical by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock valued at $1,486,000 after purchasing an additional 3,104 shares during the last quarter. Barclays PLC lifted its stake in shares of Outset Medical by 9.8% in the 4th quarter. Barclays PLC now owns 37,682 shares of the company’s stock valued at $140,000 after purchasing an additional 3,356 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Outset Medical by 11.7% in the 4th quarter. Renaissance Technologies LLC now owns 45,205 shares of the company’s stock worth $168,000 after purchasing an additional 4,745 shares during the period.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.